Suppr超能文献

下腔静脉滤器在癌症患者中的使用、并发症和取出率。

Inferior vena cava filter usage, complications, and retrieval rate in cancer patients.

机构信息

Cardiology Division, Massachusetts General Hospital, Boston, Mass.

Department of Medicine, University of Oklahoma College of Medicine, Oklahoma City.

出版信息

Am J Med. 2014 Nov;127(11):1111-1117. doi: 10.1016/j.amjmed.2014.06.025. Epub 2014 Jul 2.

Abstract

BACKGROUND

Venous thromboembolism contributes significantly to morbidity and mortality in cancer patients. Because cancer patients frequently have contraindications to anticoagulation, inferior vena cava filters are commonly placed. The use, safety, and retrieval of retrievable inferior vena cava filters in cancer patients have not been well studied.

METHODS

A retrospective review of retrievable inferior vena cava filter use at a tertiary referral hospital was conducted between January 1, 2009 and December 31, 2011. Indications for inferior vena cava filter placement, anticoagulation practices, complications, filter retrieval, and patient outcomes were analyzed for patients with and without active cancer and for cancer subtypes, including localized and metastatic cases.

RESULTS

Of 666 patients receiving retrievable inferior vena cava filters during this time period, 247 (37.1%) had active cancer. Of these, 151 (22.7%) had carcinoma, 92 (13.8%) had sarcoma, and 115 (17.3%) had metastatic disease. Overall, follow-up was available for a median of 401.0 (interquartile range: 107.5-786.5) days. Indwelling filter-related complications occurred in 19.8% of patients without cancer and 17.7% with an active cancer (P = .50). Patients with cancer were less likely to have the filter retrieved (28.0% vs 42.0%, P < .001). In multivariable analysis, cancer was not associated with filter-related complications but was associated with a lower rate of filter retrieval.

CONCLUSIONS

In a modern cohort of patients undergoing retrievable inferior vena cava filter placement, active diagnosis of cancer is not associated with a significant increase in filter-related complications, but is associated with a reduced rate of filter retrieval.

摘要

背景

静脉血栓栓塞症会显著增加癌症患者的发病率和死亡率。由于癌症患者经常有抗凝禁忌证,因此通常会放置下腔静脉滤器。尚未对癌症患者使用可回收下腔静脉滤器的情况、安全性和回收进行充分研究。

方法

回顾性分析 2009 年 1 月 1 日至 2011 年 12 月 31 日期间,在一家三级转诊医院使用可回收下腔静脉滤器的情况。分析了有和无活动性癌症患者以及癌症亚型(包括局限性和转移性病例)的下腔静脉滤器放置适应证、抗凝治疗情况、并发症、滤器回收情况和患者结局。

结果

在此期间,有 666 例患者接受了可回收下腔静脉滤器,其中 247 例(37.1%)有活动性癌症。其中,151 例(22.7%)患有癌,92 例(13.8%)患有肉瘤,115 例(17.3%)患有转移性疾病。总体而言,中位随访时间为 401.0(四分位距:107.5-786.5)天。无癌症患者中有 19.8%发生与留置滤器相关的并发症,有活动性癌症患者中有 17.7%(P =.50)。癌症患者更不可能取出滤器(28.0% vs 42.0%,P <.001)。多变量分析显示,癌症与滤器相关并发症无关,但与滤器取出率降低有关。

结论

在接受可回收下腔静脉滤器置入的现代患者队列中,癌症的活动性诊断与滤器相关并发症的发生率增加无关,但与滤器取出率降低有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验